Nuvectra Corporation (NASDAQ:NVTR) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07. Submission of Matters to a Vote of Security Holders.
The 2017 Annual Meeting of Stockholders of Nuvectra Corporation
(the Company) was held on May 23, 2017 (the Annual Meeting) at
10:00 a.m. Central Standard Time. At the Annual Meeting, the
stockholders (i)elected three directors to serve until the 2020
Annual Meeting of Stockholders; (ii)approved the Companys 2016
Equity Incentive Plan; and (iii)ratified Deloitte Touche LLP as
the Companys independent auditor for the fiscal year ending
December 31, 2017.
The matters acted upon at the Annual Meeting and the voting
tabulation for each matter are as follows:
Proposal No.1: Election of Directors
|
Nominee |
Votes For |
Votes Withheld |
Broker Non-Votes |
|
Mr. David D. Johnson |
4,373,889 |
1,175,456 |
3,626,930 |
|
Dr. Fred B. Parks, PhD |
4,093,069 |
1,456,276 |
3,626,930 |
|
Mr. Jon T. Tremmel |
4,283,993 |
1,265,352 |
3,626,930 |
Proposal No.2:Vote on Companys
2016 Equity Incentive Plan
|
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
|
|
Vote on Companys 2016 Equity Incentive |
3,527,872 |
2,014,292 |
7,181 |
3,626,930 |
Proposal No. 3: Ratification
of Deloitte Touche LLP as the Companys Independent Auditor for
the Fiscal Year EndingDecember 31,
2017
|
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
|
|
Ratification of Deloitte Touche LLP as the Companys |
9,088,918 |
86,575 |
|
|
|
Item 8.01 |
Other Events. |
On May 24, 2017, the Company posted a presentation to its
internet website located at www.nuvectramed.com that it is
utilizing in connection with meetings with certain current and
prospective investors, suppliers and customers of the Company
(the Presentation). A copy of the Presentation is attached hereto
as Exhibit99.1 and is incorporated herein by reference. The
Presentation attached as Exhibit 99.1 discloses certain
information that is not presented in accordance with United
States generally accepted accounting principles (GAAP).
|
Item9.01 |
Financial Statements and Exhibits. |
(d)Exhibits.
|
99.1 |
Presentation posted to the Nuvectra website on May 24, |
About Nuvectra Corporation (NASDAQ:NVTR)
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company’s neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim). Nuvectra Corporation (NASDAQ:NVTR) Recent Trading Information
Nuvectra Corporation (NASDAQ:NVTR) closed its last trading session up +0.14 at 9.99 with 70,797 shares trading hands.
